Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1361).(07).Neurology Case No 61. H/O Ischemic Stroke with HTN. (Prescription 1)7766

đŸŠē CORRECTED PRESCRIPTION ANALYSIS & FINAL CLINICAL ASSESSMENT

Based on MedEx Bangladesh, Harrison’s Internal Medicine, AHA/ASA & NICE Guidelines

āφāĻĒāύāĻžāϰ āϏāĻ‚āĻļā§‹āϧāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ ā§Š āύāĻŽā§āĻŦāϰ āĻ“āώ⧁āϧāϟāĻŋ Cap. Algaba 50 mg (Pregabalin)āĨ¤ āφāϗ⧇āϰ āĻŦāĻŋāĻļā§āϞ⧇āώāϪ⧇ āĻ“āώ⧁āϧāϟāĻŋāϰ āĻĒāϰāĻŋāϚ⧟ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§ŸāύāĻŋāĨ¤ āĻāĻŦāĻžāϰ MedEx āĻĨ⧇āϕ⧇ āĻāϰ Generic, Therapeutic Class, Pharmacological Class, āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻ•āĻžāϰāĻ• āĻ“ āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇āĻ›āĻŋāĨ¤

āĻĒ⧁āϰ⧋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĒ⧁āύāϰāĻžā§Ÿ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāĻšā§‡ āϏāĻ‚āĻļā§‹āϧāĻŋāϤ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϞ⧋āĨ¤

📸 āϏāĻ‚āĻļā§‹āϧāĻŋāϤ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ — C/C, O/E, ā§ŦāϟāĻŋ āĻ“āώ⧁āϧ āĻ“ Advice āϚāĻŋāĻšā§āύāĻŋāϤ āĻ›āĻŦāĻŋ

Clinical limitation: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĨ⧇āϕ⧇ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžāĻšā§āϛ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ Stroke-āĻāϰ āĻĒ⧁āϰ⧋āύ⧋ CT/MRI, āĻŦāĻ°ā§āϤāĻŽāĻžāύ Neurological Examination āĻāĻŦāĻ‚ āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŖ āωāĻĒāϏāĻ°ā§āĻ— āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤ āϤāĻžāχ āύāĻŋāĻļā§āϚāĻŋāϤ āχāϤāĻŋāĻšāĻžāϏ, āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ— āĻāĻŦāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻ…āύ⧁āĻŽāĻžāύ āφāϞāĻžāĻĻāĻžāĻ­āĻžāĻŦ⧇ āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰāĻ›āĻŋāĨ¤


ā§§. Patient Information

InformationFindings
Patient’s ageāϏāĻŽā§āĻ­āĻŦāϤ ā§Ģā§Ž āĻŦāĻ›āϰ
Dateā§§ā§§ āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ āĻŦāϞ⧇ āĻŽāύ⧇ āĻšāĻšā§āϛ⧇
Treating specialtyNeuromedicine & Medicine
Documented diseaseHTN, Ischemic Stroke
Number of prescribed drugsā§ŦāϟāĻŋ
Rehabilitation advicePhysiotherapy
Previous Stroke ImagingāϏāĻ‚āϝ⧁āĻ•ā§āϤ āύ⧇āχ

Patient History — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϕ⧀ āϞāĻŋāϖ⧇āϛ⧇āύ?

1. HTN — Hypertension

āĻŦāĻžāĻ‚āϞāĻž: āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒāĨ¤

āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ āĻŽāĻ¸ā§āϤāĻŋāĻˇā§āϕ⧇āϰ āϛ⧋āϟ āĻ“ āĻŦ⧜ āϰāĻ•ā§āϤāύāĻžāϞāĻŋāϰ āĻ•ā§āώāϤāĻŋ āϘāϟāĻžāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŦāĻ‚ Ischemic āĻ“ Hemorrhagic Stroke-āĻāϰ āĻāĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻā§āρāĻ•āĻŋāϰ āĻ•āĻžāϰāĻŖāĨ¤

Prescription-reading Confidence: 0.99

2. Ischemic Stroke

āĻŦāĻžāĻ‚āϞāĻž: āĻŽāĻ¸ā§āϤāĻŋāĻˇā§āϕ⧇ āϰāĻ•ā§āϤ āϏāϰāĻŦāϰāĻžāĻš āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻšāĻ“ā§ŸāĻžāϰ āĻ•āĻžāϰāϪ⧇ āϏāĻ‚āϘāϟāĻŋāϤ āĻ¸ā§āĻŸā§āϰ⧋āĻ•āĨ¤

āĻāĻ•āϟāĻŋ āϰāĻ•ā§āϤāύāĻžāϞāĻŋāϤ⧇ Thrombus āĻ…āĻĨāĻŦāĻž Embolus āĻĻā§āĻŦāĻžāϰāĻž āϰāĻ•ā§āϤāĻĒā§āϰāĻŦāĻžāĻš āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻšāϞ⧇ āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ āĻŽāĻ¸ā§āϤāĻŋāĻˇā§āϕ⧇āϰ āĻ…āĻ‚āĻļ⧇ Ischemia āĻĻ⧇āĻ–āĻž āĻĻā§‡ā§ŸāĨ¤

Prescription-reading Confidence: 0.98

3. Additional History

Ischemic Stroke-āĻāϰ āĻĒāϰ⧇ āφāϰāĻ“ āĻāĻ•āϟāĻŋ āϏāĻ‚āĻ•ā§āώāĻŋāĻĒā§āϤ āύ⧋āϟ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϏ⧇āϟāĻŋ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻĒ⧜āĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

āϤāĻžāχ āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āϏāĻŽā§Ÿ, āĻŽāĻ¸ā§āϤāĻŋāĻˇā§āϕ⧇āϰ āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ…āĻ‚āĻļ āĻ…āĻĨāĻŦāĻž āĻļāϰ⧀āϰ⧇āϰ āϕ⧋āύ āĻĒāĻžāĻļ āĻĻ⧁āĻ°ā§āĻŦāĻ˛â€”āĻāϏāĻŦ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰ⧇ āĻŦāϞāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤


⧍. C/C — Chief Complaints

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ C/C-āĻāϰ āύāĻŋāĻšā§‡ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§Ÿ:

  1. HTN
  2. Ischemic Stroke
  3. āĻāĻ•āϟāĻŋ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āύ⧋āϟāĨ¤

Clinical observation: āĻāĻ–āĻžāύ⧇ āĻŽā§‚āϞāϤ āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ…āϏ⧁āĻ¸ā§āĻĨāϤāĻžāϰ āϤāĻĨā§āϝ āϞ⧇āĻ–āĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āωāĻĒāϏāĻ°ā§āĻ—āϗ⧁āϞ⧋ āĻĒ⧃āĻĨāĻ•āĻ­āĻžāĻŦ⧇ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤

āϝ⧇āĻŽāύ āĻšāĻžāϤ-āĻĒāĻž āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž, āĻŦā§āϝāĻĨāĻž, āĻāĻŋāύāĻāĻŋāύ āĻ•āϰāĻž, āĻšāĻžāρāϟāĻžāϰ āĻ…āϏ⧁āĻŦāĻŋāϧāĻž āĻ…āĻĨāĻŦāĻž āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋāϤ⧇ āϟāĻžāĻ¨â€”āĻāϏāĻŦ⧇āϰ āωāĻĒāĻ¸ā§āĻĨāĻŋāϤāĻŋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĨ⧇āϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤


ā§Š. O/E — On Examination

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āĻāĻ•āϟāĻŋ Reading āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

BP: āϏāĻŽā§āĻ­āĻŦāϤ 110/80 mmHgāĨ¤

āϤāĻŦ⧇ āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āĻ…āĻ¸ā§āĻĒāĻˇā§āϟāĨ¤ āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āύ⧇āĻ“ā§ŸāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

ExaminationDocumentation
Blood PressureāϏāĻŽā§āĻ­āĻŦāϤ 110/80 mmHg
PulseāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Muscle PowerāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Muscle ToneāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Deep Tendon ReflexesāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Plantar ResponseāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Cranial Nerve ExaminationāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
GaitāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Sensory ExaminationāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ

Clinical Interpretation

āĻŦāĻ°ā§āϤāĻŽāĻžāύ Functional Deficit āĻ…āĻĨāĻŦāĻž Post-Stroke Spasticity āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāϰ āĻŽāϤ⧋ Neurological Examination āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤


ā§Ē. Investigations

āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āύāϤ⧁āύ āϕ⧋āύ⧋ Laboratory āĻŦāĻž Imaging Investigation āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāύāĻŋāĨ¤

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• CT Brain, MRI Brain, ECG āĻŦāĻž Lipid Profile āĻĻāĻŋā§Ÿā§‡āϛ⧇āĻ¨â€”āĻāĻŽāύ āϤāĻĨā§āϝ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

āύāĻŋāĻšā§‡ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ Clinical Assessment-āĻ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž āφāϞāĻžāĻĻāĻžāĻ­āĻžāĻŦ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤


ā§Ģ. Advice — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϕ⧀ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ?

1. Physiotherapy

āĻŦāĻžāĻ‚āϞāĻž: āĻĢāĻŋāϜāĻŋāĻ“āĻĨ⧇āϰāĻžāĻĒāĻŋāĨ¤

āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āĻĒāϰ⧇ āĻĒ⧇āĻļāĻŋāϰ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž, āĻ­āĻžāϰāϏāĻžāĻŽā§āϝāĻšā§€āύāϤāĻž, āĻšāĻžāρāϟāĻžāϚāϞāĻžāϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻāĻŦāĻ‚ āĻĻ⧈āύāĻ¨ā§āĻĻāĻŋāύ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āωāĻ¨ā§āύāϤ āĻ•āϰāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤

NICE NG236 (2023) āĻ…āύ⧁āϝāĻžā§Ÿā§€ Stroke Rehabilitation āϰ⧋āĻ—ā§€āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ“ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ Functional Problem āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĒāϰāĻŋāϚāĻžāϞāĻŋāϤ āĻšāĻ“ā§ŸāĻž āωāϚāĻŋāϤāĨ¤

2. Additional Bengali Advice

āĻĢāĻŋāϜāĻŋāĻ“āĻĨ⧇āϰāĻžāĻĒāĻŋāϰ āύāĻŋāĻšā§‡ āφāϰāĻ“ āĻāĻ•āϟāĻŋ āĻŦāĻžāĻ‚āϞāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϏ⧇āϟāĻŋāϰ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻžāĻ•ā§āϝ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āύ⧟āĨ¤

āϭ⧁āϞ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤ⧇ āĻāϟāĻŋāϕ⧇ Unconfirmed āĻšāĻŋāϏ⧇āĻŦ⧇ āϰāĻžāĻ–āĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤


ā§Ŧ. Complete Drug Analysis — MedEx Verified

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āύāĻŋāĻšā§‡āϰ āĻ›ā§ŸāϟāĻŋ āĻ“āώ⧁āϧ āĻĻ⧇āĻ–āĻž āϝāĻžāĻšā§āϛ⧇āĨ¤

No.Prescribed BrandGenericStrength
1EcosprinAspirin75 mg
2ATVAtorvastatin Calcium10 mg
3AlgabaPregabalin50 mg
4Reservix*Aceclofenac100 mg
5LosectilOmeprazole20 mg
6Beklo*Baclofen5 mg

ā§Ē āĻ“ ā§Ŧ āύāĻŽā§āĻŦāϰ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄā§‡āϰ āύāĻžāĻŽ āφāϗ⧇āϰ āĻĒāĻžāĻ  āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝāĻ­āĻžāĻŦ⧇ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āĻ“āώ⧁āϧ⧇āϰ āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ āĻĻāĻŋā§Ÿā§‡ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻ­āĻžāϞ⧋āĨ¤

Drug 1. Tab. Ecosprin 75 mg

Generic Name: Aspirin 75 mg
Bangladesh Brand: Ecosprin
Manufacturer: ACME Laboratories Ltd.

MedEx Therapeutic Class: Anti-platelet drugs.

Pharmacological Class: Irreversible Cyclooxygenase-1 Inhibitor; Antiplatelet Agent.

Unit Price: ā§ŗ0.80
Strip Price: ā§ŗ11.20 (ā§§ā§ĒāϟāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ)āĨ¤

Other Available Strength: Ecosprin 81 mgāĨ¤

Use of Purpose

Aspirin āĻ•āĻŽ āĻŽāĻžāĻ¤ā§āϰāĻžā§Ÿ Thromboxane A₂ āĻ‰ā§ŽāĻĒāĻžāĻĻāύ āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻ•āϰ⧇ Platelet Aggregation āĻ•āĻŽāĻžā§ŸāĨ¤

āĻāϟāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§Ÿ:

  1. Non-cardioembolic Ischemic Stroke-āĻāϰ Secondary PreventionāĨ¤
  2. Transient Ischemic Attack (TIA)āĨ¤
  3. Myocardial Infarction-āĻāϰ āĻĒāϰ⧇āĨ¤
  4. āύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ Coronary Artery Disease-āĻāϰ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇āĨ¤

Why Prescribed in This Patient?

āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Ischemic Stroke-āĻāϰ āĻĒāϰ⧇ āĻĒ⧁āύāϰāĻžā§Ÿ āϰāĻ•ā§āϤ āϜāĻŽāĻžāϟāϜāύāĻŋāϤ āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āĻā§āρāĻ•āĻŋ āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝāĨ¤

Clinical Assessment: Non-cardioembolic Stroke-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āωāĻĒāϝ⧁āĻ•ā§āϤ Antiplatelet āĻšāĻŋāϏ⧇āĻŦ⧇ Aspirin āĻŦā§āϝāĻŦāĻšāĻžāϰ Guideline-supportedāĨ¤

āϤāĻŦ⧇ Cardioembolic Stroke, āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ Atrial Fibrillation āĻĨāĻžāĻ•āϞ⧇ Anticoagulant āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.95 — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Prescribing IndicationāĨ¤

MedEx: Ecosprin 75 mg

Other BD Brands: Carva 75 mg, Cardoprin 75 mgāĨ¤


Drug 2. Tab. ATV 10 mg

Generic Name: Atorvastatin Calcium 10 mg
Brand Name: ATV
Manufacturer: Delta Pharma PLC.

MedEx Therapeutic Class: Other Anti-anginal & Anti-ischaemic drugs, Statins.

Pharmacological Class: HMG-CoA Reductase Inhibitor.

Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ50.00 (ā§§ā§ĻāϟāĻŋ)āĨ¤

Other Available ATV Strengths: 20 mg, 40 mgāĨ¤

Use of Purpose

  1. HypercholesterolemiaāĨ¤
  2. Mixed DyslipidemiaāĨ¤
  3. Atherosclerotic Cardiovascular DiseaseāĨ¤
  4. Ischemic Stroke-āĻāϰ Secondary PreventionāĨ¤
  5. Cardiovascular Event Risk ReductionāĨ¤

Why Prescribed in This Patient?

āϏāĻŽā§āĻ­āĻŦāϤ āĻ­āĻŦāĻŋāĻˇā§āϝāϤ⧇ Ischemic Stroke āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Atherosclerotic Cardiovascular Event-āĻāϰ āĻā§āρāĻ•āĻŋ āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝāĨ¤

Clinical Assessment

Atorvastatin 10 mg āĻāĻ•āϟāĻŋ Moderate-intensity Statin DoseāĨ¤

AHA/ASA 2021 Guideline āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ…āύ⧇āĻ• Ischemic Stroke āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ High-intensity Statin āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻŦāĻŋāĻļ⧇āώāϤ Atherosclerotic Disease āĻĨāĻžāĻ•āϞ⧇ LDL-C Target āϏāĻžāϧāĻžāϰāĻŖāϤ <70 mg/dLāĨ¤

āϰ⧋āĻ—ā§€āϰ LDL-C, Liver Function, āĻ“āώ⧁āϧ⧇āϰ āϏāĻšāύāĻļā§€āϞāϤāĻž āĻāĻŦāĻ‚ Stroke Etiology āύāĻž āĻœā§‡āύ⧇ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻĄā§‹āϜ āĻ…āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.95

MedEx: ATV 10 mg

Other BD Brands: Atova 10 mg āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Atorvastatin preparationsāĨ¤


Drug 3. Cap. ALGABA 50 mg — Corrected

āĻāϟāĻžāχ āφāĻĒāύāĻžāϰ āĻĻ⧇āĻ“ā§ŸāĻž āϏāĻ‚āĻļā§‹āϧāύāĨ¤

Verified Drug Information

Brand Name: Algaba 50 mg
Generic Name: Pregabalin 50 mg
Manufacturer: Al-Madina Pharmaceuticals Ltd.

MedEx Therapeutic Class

Adjunct anti-epileptic drugs, Primary anti-epileptic drugs.

āĻāϟāĻŋ MedEx-āĻ āωāĻ˛ā§āϞ⧇āĻ–āĻŋāϤ Therapeutic ClassificationāĨ¤ āϤāĻŦ⧇ āĻ“āώ⧁āϧāϟāĻŋāϰ āĻ…āĻ¨ā§āϝāϤāĻŽ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Clinical Use āĻšāϞ⧋ Neuropathic Pain ManagementāĨ¤

Pharmacological Class

Gabapentinoid Anticonvulsant; α₂δ-subunit Ligand of Voltage-Gated Calcium Channels.

Pregabalin āϏāϰāĻžāϏāϰāĻŋ GABA-A āĻŦāĻž GABA-B Receptor Agonist āύ⧟āĨ¤

Unit & Strip Price

InformationDetails
GenericPregabalin
Strength50 mg
Unit Priceā§ŗ12.00
Strip Priceā§ŗ120.00
30 Capsulesā§ŗ360.00
Other Algaba Strengths75 mg, 150 mg

āĻāχ āϤāĻĨā§āϝ āϏāϰāĻžāϏāϰāĻŋ MedEx āĻĨ⧇āϕ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

Use of Purpose

Pregabalin āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ:

  1. Neuropathic Pain — āĻ¸ā§āύāĻžā§Ÿā§āϜāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāĨ¤
  2. Diabetic Peripheral Neuropathy — āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻ¸ā§āύāĻžā§Ÿā§āϰ āĻŦā§āϝāĻĨāĻžāĨ¤
  3. Postherpetic Neuralgia — āĻšāĻžāϰāĻĒāĻŋāϏ āĻœā§‹āĻ¸ā§āϟāĻžāϰ⧇āϰ āĻĒāϰ⧇ āĻ¸ā§āύāĻžā§Ÿā§āϜāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāĨ¤
  4. Fibromyalgia — āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻŦā§āϝāĻžāĻĒāĻ• āĻŦā§āϝāĻĨāĻžāϰ āĻāĻ•āϟāĻŋ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāĨ¤
  5. Partial-onset Seizures — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻ“āώ⧁āϧ⧇āϰ āϏāĻ™ā§āϗ⧇ āϏāĻšāĻžā§ŸāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤
  6. Central Neuropathic Pain — āύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ āϰ⧋āĻ—ā§€āϰ āϕ⧇āĻ¨ā§āĻĻā§āĻ°ā§€ā§Ÿ āĻ¸ā§āύāĻžā§Ÿā§āϤāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻ•ā§āώāϤāĻŋāϰ āĻ•āĻžāϰāϪ⧇ āĻŦā§āϝāĻĨāĻžāĨ¤

Why Doctor Prescribed Algaba in This Patient?

āφāĻŽāĻžāϰ Working Clinical Interpretation āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻšāϞ⧋:

Suspected Post-Stroke Neuropathic Pain.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āĻĒāϰ āĻ¸ā§āύāĻžā§Ÿā§āϜāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āĻĒāϰ⧇ āĻ•āĻŋāϛ⧁ āϰ⧋āĻ—ā§€āϰ āĻŦā§āϝāĻĨāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āϝāĻž āϏāĻžāϧāĻžāϰāĻŖ āĻĒ⧇āĻļāĻŋ āĻŦāĻž āĻ…āĻ¸ā§āĻĨāĻŋāϏāĻ¨ā§āϧāĻŋāϰ āĻŦā§āϝāĻĨāĻž āĻĨ⧇āϕ⧇ āĻ­āĻŋāĻ¨ā§āύāĨ¤

āϝ⧇āĻŽāύ:

  • āĻœā§āĻŦāĻžāϞāĻžāĻĒā§‹ā§œāĻž āϧāϰāύ⧇āϰ āĻŦā§āϝāĻĨāĻžāĨ¤
  • āĻŦāĻŋāĻĻā§āĻ¯ā§ā§ŽāĻ¸ā§āĻĒ⧃āĻˇā§āϟ āĻšāĻ“ā§ŸāĻžāϰ āĻŽāϤ⧋ āĻŦā§āϝāĻĨāĻžāĨ¤
  • āĻ¸ā§āĻĒāĻ°ā§āĻļ⧇ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻŦā§āϝāĻĨāĻžāĨ¤
  • āϏ⧁āϚ āĻĢā§‹āϟāĻžāϰ āĻŽāϤ⧋ āĻ…āύ⧁āĻ­ā§‚āϤāĻŋāĨ¤
  • āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ…āĻ‚āĻļ⧇ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• SensationāĨ¤

āϤāĻŦ⧇ āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻāϏāĻŦ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āωāĻĒāĻ¸ā§āĻĨāĻŋāϤāĻŋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤

āϤāĻžāχ āĻļ⧁āϧ⧁ Algaba āϞ⧇āĻ–āĻž āφāϛ⧇ āĻŦāϞ⧇ Central Post-Stroke Pain Syndrome āύāĻŋāĻļā§āϚāĻŋāϤ Diagnosis āĻšāĻŋāϏ⧇āĻŦ⧇ āϞ⧇āĻ–āĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Guideline Support

NICE CG173 āĻ…āύ⧁āϝāĻžā§Ÿā§€ Neuropathic Pain-āĻāϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻ“āώ⧁āϧ⧇āϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒāϗ⧁āϞ⧋āϰ āĻŽāĻ§ā§āϝ⧇ āĻ°ā§Ÿā§‡āϛ⧇ Pregabalin, Gabapentin, Duloxetine āĻ“ AmitriptylineāĨ¤

Clinical Precautions

Pregabalin-āĻāϰ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇:

  • Dizziness
  • Somnolence
  • Peripheral Edema
  • Blurred Vision
  • Balance Impairment

āĻŦāĻŋāĻļ⧇āώ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: Pregabalin āĻāĻŦāĻ‚ Baclofen āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇ āϘ⧁āĻŽāϘ⧁āĻŽ āĻ­āĻžāĻŦ, āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž āĻ“ āĻĒā§œā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āĻā§āρāĻ•āĻŋ āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Kidney Function āĻ…āύ⧁āϝāĻžā§Ÿā§€ Pregabalin-āĻāϰ āĻĄā§‹āϜ āϏāĻŽāĻ¨ā§āĻŦ⧟ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻ āĻ›āĻžā§œāĻž āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āϏ⧇āĻŦāύ⧇āϰ āĻĒāϰ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ›āĻžā§œāĻž āĻšāĻ āĻžā§Ž āĻŦāĻ¨ā§āϧ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤

Bangladesh Available Brands

BrandGenericStrength
AlgabaPregabalin50 mg
NervalinPregabalin50 mg
NeurolinPregabalin50 mg
PrelinPregabalin50 mg
NeuricaPregabalin50 mg
NeurovanPregabalin50 mg

āĻāϏāĻŦ āĻāĻ•āχ Generic-āĻāϰ āωāĻĻāĻžāĻšāϰāĻŖ; āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤāĻ­āĻžāĻŦ⧇ āĻ¸ā§āĻŦ⧟āĻ‚āĻ•ā§āϰāĻŋ⧟āĻ­āĻžāĻŦ⧇ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āύ⧟āĨ¤

MedEx Direct Link

Algaba 50 mg — Pregabalin

Confidence:

  • Drug Identification: 1.00
  • Suspected Neuropathic Pain Indication: 0.60
  • Confirmed Central Post-Stroke Pain Diagnosis: āĻĒā§āϰāĻŽāĻžāĻŖ āĻ…āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ

Drug 4. Tab. Reservix 100 mg — Probable Identification

Generic Name: Aceclofenac 100 mg
Brand Name: Reservix
Manufacturer: Incepta Pharmaceuticals Ltd.

MedEx Therapeutic Class: Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs).

Pharmacological Class: Phenylacetic Acid Derivative NSAID; Cyclooxygenase Inhibitor.

Unit Price: ā§ŗ5.70
Strip Price: ā§ŗ57.00āĨ¤

Other Available Strength: Reservix SR 200 mgāĨ¤

Use of Purpose

  1. OsteoarthritisāĨ¤
  2. Rheumatoid ArthritisāĨ¤
  3. Ankylosing SpondylitisāĨ¤
  4. Musculoskeletal PaināĨ¤
  5. Inflammatory PaināĨ¤

Why Prescribed in This Patient?

āϏāĻŽā§āĻ­āĻŦāϤ āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻš āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝāĨ¤

āĻ•āĻŋāĻ¨ā§āϤ⧁ āϰ⧋āĻ—ā§€āϰ āĻŦā§āϝāĻĨāĻžāϰ āĻ‰ā§ŽāϏ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĨ¤

âš ī¸ Important Safety Concern

āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Ischemic Stroke āĻĨāĻžāĻ•āĻž āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ Aceclofenac āĻ…āĻ¤ā§āϝāĻ¨ā§āϤ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Medication Review-āĻāϰ āĻŦāĻŋāώ⧟āĨ¤

āϝ⧁āĻ•ā§āϤāϰāĻžāĻœā§āϝ⧇āϰ MHRA āĻ…āύ⧁āϝāĻžā§Ÿā§€ Established Cerebrovascular Disease-āĻ Aceclofenac contraindicatedāĨ¤

āĻ āĻ›āĻžā§œāĻž Aspirin-āĻāϰ āϏāĻ™ā§āϗ⧇ NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϞ⧇ Gastrointestinal Bleeding-āĻāϰ āĻā§āρāĻ•āĻŋāĻ“ āĻŦ⧃āĻĻā§āϧāĻŋ āĻĒ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āϏ⧁āϤāϰāĻžāĻ‚ āĻ“āώ⧁āϧāϟāĻŋ āϏāĻ¤ā§āϝāĻŋāχ Reservix āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰ⧇, āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĄā§‹āĻœā§‡āϰ āφāϗ⧇ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻžāχāĻŦāĻŋāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻāϰ āωāĻĒāϝ⧁āĻ•ā§āϤāϤāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

āĻāϟāĻŋ Stroke Prevention-āĻāϰ āĻ“āώ⧁āϧ āύ⧟āĨ¤

MedEx: Reservix 100 mg

Alternative BD Brands: Acefenac, Acenac, PreservināĨ¤


Drug 5. Cap. Losectil 20 mg

Generic Name: Omeprazole 20 mg
Manufacturer: Eskayef Pharmaceuticals Ltd.

MedEx Therapeutic Class: Proton Pump Inhibitor.

Pharmacological Class: Gastric Hâē/Kâē-ATPase Inhibitor.

Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ50.00 āĻ…āĻĨāĻŦāĻž ā§ŗ60.00, āĻĒā§āϝāĻžāϕ⧇āϰ āφāĻ•āĻžāϰ āĻ…āύ⧁āϝāĻžā§Ÿā§€āĨ¤

Other Available Strengths: 10 mg, 40 mgāĨ¤

Use of Purpose

  1. GERDāĨ¤
  2. Peptic Ulcer DiseaseāĨ¤
  3. Gastritis-associated acid symptomsāĨ¤
  4. NSAID-associated Gastric UlcerāĨ¤
  5. āύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ āϰ⧋āĻ—ā§€āϰ GastroprotectionāĨ¤

Why Doctor Prescribed?

āϏāĻŽā§āĻ­āĻŦāϤ Aspirin āĻāĻŦāĻ‚ Painkiller āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϏāĻŽā§Ÿ āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āĻ…ā§āϝāĻžāϏāĻŋāĻĄāϜāύāĻŋāϤ āϏāĻŽāĻ¸ā§āϝāĻž āĻŦāĻž Gastrointestinal Ulcer-āĻāϰ āĻā§āρāĻ•āĻŋ āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇āĨ¤

Clinical Limitation: āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Gastric Ulcer āĻŦāĻž GI Bleeding-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āϜāĻžāύāĻž āύ⧇āχāĨ¤

MedEx: Losectil 20 mg

Alternative BD Brand: Seclo 20 mgāĨ¤


Drug 6. Tab. Beklo 5 mg — Probable Identification

Generic Name: Baclofen 5 mg
Manufacturer: Opsonin Pharma Ltd.

MedEx Therapeutic Class: Centrally acting Skeletal Muscle Relaxants.

Pharmacological Class: GABA-B Receptor Agonist; Centrally Acting Antispastic Agent.

Unit Price: ā§ŗ5.50
Strip Price: ā§ŗ77.00āĨ¤

Other Available Strengths: 10 mg, 25 mgāĨ¤ āĻāĻ›āĻžā§œāĻž Oral Solution āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Use of Purpose

  1. SpasticityāĨ¤
  2. Muscle SpasmāĨ¤
  3. Multiple Sclerosis-associated SpasticityāĨ¤
  4. Spinal Cord Injury-associated SpasticityāĨ¤
  5. āύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ Post-Stroke SpasticityāĨ¤

Why Doctor Prescribed?

āϏāĻŽā§āĻ­āĻŦāϤ āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āĻĒāϰ⧇ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋāϤ⧇ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϟāĻžāύ āĻŦāĻž Spasticity āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝāĨ¤

āϤāĻŦ⧇ āϰ⧋āĻ—ā§€āϰ Muscle Tone, Reflexes āĻāĻŦāĻ‚ Modified Ashworth Scale-āĻāϰ āĻĢāϞ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

Clinical Assessment

NICE NG236 (2023) āĻ…āύ⧁āϝāĻžā§Ÿā§€ Generalised Post-Stroke Spasticity āĻĨāĻžāĻ•āϞ⧇ Oral Baclofen āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āϝāĻžā§Ÿ, āϤāĻŦ⧇ adverse effects āύāĻŋāĻŦāĻŋ⧜āĻ­āĻžāĻŦ⧇ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Baclofen āϘ⧁āĻŽāϘ⧁āĻŽ āĻ­āĻžāĻŦ, āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž āĻāĻŦāĻ‚ Muscle Weakness āϏ⧃āĻˇā§āϟāĻŋ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āϰ⧋āĻ—ā§€āϰ āĻŽāĻ§ā§āϝ⧇ āĻāϰ āϏāĻšāύāĻļā§€āϞāϤāĻž āĻ•āĻŽ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

MedEx: Beklo 5 mg

Confidence:

  • Drug Identification: 0.85
  • Possible Spasticity-related Indication: 0.70

ā§­. Medication Summary — āϕ⧇āύ āϕ⧋āύ āĻ“āώ⧁āϧ?

DrugMain Purpose in This CaseAssessment
Ecosprin 75āĻĒ⧁āύāϰāĻžā§Ÿ Ischemic Stroke āĻĒā§āϰāϤāĻŋāϰ⧋āϧāωāĻĒāϝ⧁āĻ•ā§āϤ Stroke Subtype āĻšāϞ⧇ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ
ATV 10LDL āĻ•āĻŽāĻžāύ⧋ āĻ“ Vascular Risk ReductionStatin Intensity Review āĻĒā§āĻ°ā§Ÿā§‹āϜāύ
Algaba 50āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Neuropathic PaināĻŦā§āϝāĻĨāĻžāϰ History āĻ“ Examination āĻĒā§āĻ°ā§Ÿā§‹āϜāύ
Reservix 100āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Musculoskeletal PainStroke History āĻĨāĻžāĻ•āĻžā§Ÿ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Safety Concern
Losectil 20Gastric Acid Suppression / GastroprotectionIndication āĻ“ Duration Review
Beklo 5āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Spasticity ControlTone āĻ“ Functional Assessment āĻĒā§āĻ°ā§Ÿā§‹āϜāύ

āύ⧋āϟ: āĻ“āώ⧁āϧ⧇āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĻ⧇āϖ⧇ āϰ⧋āĻ—ā§€āϰ āϏāĻŦ āϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤ Prescription Indication āĻāĻŦāĻ‚ Confirmed Diagnosis āĻāĻ• āĻŦāĻŋāώ⧟ āύ⧟āĨ¤

āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻžā§Ÿ āĻ•āĻŋāϛ⧁ āĻ“āώ⧁āϧ⧇āϰ āϏ⧇āĻŦāύ⧇āϰ āϏāĻŽā§Ÿ āĻŦā§‹āĻāĻž āϗ⧇āϞ⧇āĻ“ āϏāĻŦ āĻĄā§‹āĻœā§‡āϰ Frequency āĻ“ Duration āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤ āϤāĻžāχ āϭ⧁āϞāĻ­āĻžāĻŦ⧇ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ Dosage Schedule āϤ⧈āϰāĻŋ āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤


ā§Ž. Clinical Definition & Pathophysiology

Ischemic Stroke

āĻŽāĻ¸ā§āϤāĻŋāĻˇā§āϕ⧇āϰ āϕ⧋āύ⧋ āĻ…āĻ‚āĻļ⧇ āϰāĻ•ā§āϤ āϏāϰāĻŦāϰāĻžāĻš āĻšāĻ āĻžā§Ž āĻ•āĻŽā§‡ āϗ⧇āϞ⧇ āĻŦāĻž āĻŦāĻ¨ā§āϧ āĻšā§Ÿā§‡ āϗ⧇āϞ⧇ Neurological Injury āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻĒā§āϰāϧāĻžāύ Mechanism:

  1. Large Artery AtherosclerosisāĨ¤
  2. Small Vessel OcclusionāĨ¤
  3. CardioembolismāĨ¤
  4. āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…āĻĨāĻŦāĻž āĻ…āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āĻ•āĻžāϰāĻŖāĨ¤

āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ HTN Small Vessel Disease āĻāĻŦāĻ‚ Atherosclerosis-āĻāϰ āĻā§āρāĻ•āĻŋ āĻŦ⧃āĻĻā§āϧāĻŋ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Post-Stroke Complications

āϰ⧋āĻ—ā§€āϰ Stroke-āĻāϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ āĻ“ āϤ⧀āĻŦā§āϰāϤāĻžāϰ āĻ“āĻĒāϰ āύāĻŋāĻ°ā§āĻ­āϰ āĻ•āϰ⧇ āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϤ⧇ āĻĒāĻžāϰ⧇:

  • Hemiparesis
  • Hemiplegia
  • Dysphasia/Aphasia
  • Sensory Impairment
  • Gait Disturbance
  • Spasticity
  • Central Post-Stroke Pain

āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āϕ⧋āύāϟāĻŋ āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āφāϛ⧇, āϤāĻž Physical Examination āĻ›āĻžā§œāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤


⧝. My Clinical Working Diagnosis

A. Documented Diagnoses

1. History of Ischemic Stroke

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āχāĻ¸ā§āϕ⧇āĻŽāĻŋāĻ• āĻ¸ā§āĻŸā§āϰ⧋āϕ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

2. History of Hypertension

āĻŦāĻžāĻ‚āϞāĻž: āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

B. Conditions Requiring Confirmation

3. Possible Post-Stroke Neuropathic Pain

āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻŸā§āϰ⧋āĻ•-āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻ¸ā§āύāĻžā§Ÿā§āϜāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

āĻāϟāĻŋ Algaba āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻāĻ•āϟāĻŋ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž; āύāĻŋāĻļā§āϚāĻŋāϤ Diagnosis āύ⧟āĨ¤

4. Possible Post-Stroke Spasticity

āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻŸā§āϰ⧋āĻ•-āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋāϰ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϟāĻžāύ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

āĻāϟāĻŋ Beklo āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž; āύāĻŋāĻļā§āϚāĻŋāϤ Diagnosis āύ⧟āĨ¤

Diagnostic Confidence

AssessmentConfidenceEvidence
Previous Ischemic Stroke documented0.98āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž
Hypertension documented0.99āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž
Current Residual Neurological Deficit0.60Rehabilitation advice, āĻ•āĻŋāĻ¨ā§āϤ⧁ Examination āύ⧇āχ
Neuropathic Pain0.60Pregabalin prescribed
Spasticity0.70Baclofen prescribed
Specific Stroke EtiologyāύāĻŋāĻ°ā§āϧāĻžāϰāĻŖāϝ⧋āĻ—ā§āϝ āύ⧟Imaging āĻ“ Cardiac Workup āύ⧇āχ

āĻāχ Confidence Score-āϗ⧁āϞ⧋ āύāĻĨāĻŋāĻĒāĻžāĻ  āĻ“ Clinical Interpretation-āĻāϰ āφāύ⧁āĻŽāĻžāύāĻŋāĻ• āύāĻŋāĻļā§āϚ⧟āϤāĻž āĻĒā§āϰāĻ•āĻžāĻļ āĻ•āϰ⧇; āϰ⧋āĻ— āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžā§Ÿ āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ Probability āύ⧟āĨ¤


ā§§ā§Ļ. Doctor’s Dx vs My Working Dx

Doctor’s DocumentationMy AssessmentComparison
HTNHistory of HypertensionSimilar
Ischemic StrokeHistory of Ischemic StrokeSimilar
Neuropathic PainPossibleDoctor āϏāϰāĻžāϏāϰāĻŋ āϞ⧇āϖ⧇āύāύāĻŋ
SpasticityPossibleDoctor āϏāϰāĻžāϏāϰāĻŋ āϞ⧇āϖ⧇āύāύāĻŋ

Final Justification

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āĻŽā§‚āϞ āϰ⧋āϗ⧇āϰ āϏāĻ™ā§āϗ⧇ āφāĻŽāĻžāϰ Working Diagnosis āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤

āϤāĻŦ⧇ Algaba āĻ“ Beklo āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ Neuropathic Pain āĻāĻŦāĻ‚ Spasticity-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

āĻāχ āĻĻ⧁āϟāĻŋ āϏāĻŽāĻ¸ā§āϝāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āύāĻž āĻšāĻ“ā§ŸāĻž āĻĒāĻ°ā§āϝāĻ¨ā§āϤ Diagnosis-āĻ āύāĻŋāĻļā§āϚāĻŋāϤ āϰ⧋āĻ— āĻšāĻŋāϏ⧇āĻŦ⧇ āϞ⧇āĻ–āĻž āωāϚāĻŋāϤ āύ⧟āĨ¤


ā§§ā§§. Differential Diagnosis

āĻŦāĻ°ā§āϤāĻŽāĻžāύ āωāĻĒāϏāĻ°ā§āĻ— āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦāĻŋāĻŦ⧇āϚāύāĻžā§Ÿ āϰāĻžāĻ–āϤ⧇ āĻšāĻŦ⧇:

Differential DiagnosisClinical Clue
Residual Deficit Following Previous StrokeāĻĒ⧁āϰ⧋āύ⧋ āĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž
Recurrent Ischemic StrokeāύāϤ⧁āύ Neurological Deficit
Central Post-Stroke PainStroke-āĻāϰ āĻĒāϰ⧇ Neuropathic Pain
Post-Stroke SpasticityIncreased Muscle Tone, Hyperreflexia
Peripheral NeuropathyPeripheral Sensory Symptoms
Cervical MyelopathyGait Problem, Hyperreflexia, Limb Weakness

āύāϤ⧁āύ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻĨāĻžāĻ•āϞ⧇ āĻĒā§āϰāĻĨāĻŽā§‡āχ Acute Stroke Exclusion āϜāϰ⧁āϰāĻŋāĨ¤


⧧⧍. Recommended Investigations

āĻāϗ⧁āϞ⧋ āύāϤ⧁āύ Clinical Recommendation; āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϤāĻžāϞāĻŋāĻ•āĻž āύ⧟āĨ¤

InvestigationPurpose
Previous CT/MRI Brain ReviewStroke Type āĻ“ Lesion Location
MRI BraināύāϤ⧁āύ Stroke āĻŦāĻž Diagnosis āĻ…āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϞ⧇
ECGAtrial Fibrillation
Holter MonitoringOccult AF āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇
EchocardiographyCardioembolic Source, āϝāĻ–āύ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāϤ
Lipid ProfileLDL-C āĻ“ Statin Response
HbA1cDiabetes Screening
Serum Creatinine/eGFRRenal Function āĻ“ Drug-dose Review
Serum ElectrolytesMetabolic Assessment
CBCAnaemia āĻ“ Platelet Evaluation
LFTStatin-related Clinical Monitoring, āϝāĻ–āύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ
Carotid/Vascular ImagingStroke Etiology āĻ…āύ⧁āϝāĻžā§Ÿā§€

Neurological Examination

Muscle Power, Tone, Sensation, Reflexes, Plantar Response, Coordination, Gait āĻ“ Functional Assessment āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Spasticity āĻĨāĻžāĻ•āϞ⧇ Modified Ashworth Scale āĻāĻŦāĻ‚ Functional Limitation āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āĻ•āϰāĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤


ā§§ā§Š. Bangladesh Doctors Commonly Use Which Drugs?

āϰ⧋āϗ⧇āϰ āϧāϰāύ āĻ“ Clinical Indication āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āĻĒā§āϰāϚāϞāĻŋāϤ āĻ•āĻŋāϛ⧁ Generic āĻ“ Brand-āĻāϰ āωāĻĻāĻžāĻšāϰāĻŖ āύāĻŋāĻšā§‡ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϞ⧋āĨ¤

āĻāϗ⧁āϞ⧋ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āύāϤ⧁āύ Prescription āύ⧟āĨ¤ āϏāĻŦ āĻ“āώ⧁āϧ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āϤāĻžāϞāĻŋāĻ•āĻžāĻ“ āύ⧟āĨ¤

No.GenericBangladesh Brand ExampleClinical Indication
1AspirinEcosprin, CarvaNon-cardioembolic Stroke Prevention
2ClopidogrelClopid, ClognilāĻŦāĻŋāĻ•āĻ˛ā§āĻĒ Antiplatelet
3AtorvastatinATV, AtovaLDL Reduction
4RosuvastatinRosuva, RosutinLDL Reduction
5EzetimibeāĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ BD BrandāĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ LDL Reduction
6AmlodipineAmdocalHypertension, āωāĻĒāϝ⧁āĻ•ā§āϤ āϰ⧋āĻ—ā§€
7PregabalinAlgaba, NeurolinNeuropathic Pain
8GabapentināĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ BD BrandNeuropathic Pain
9DuloxetineāĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ BD BrandNeuropathic Pain
10AmitriptylineāĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ BD BrandNeuropathic Pain
11BaclofenBekloāύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ Generalised Spasticity
12OmeprazoleLosectil, SecloāωāĻĒāϝ⧁āĻ•ā§āϤ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ Gastroprotection

AHA/ASA Stroke Prevention Guideline āĻāĻŦāĻ‚ NICE Neuropathic Pain Guideline āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ“āώ⧁āϧ āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āϰ⧋āĻ—ā§€āϰ Stroke Subtype, Associated Conditions, Contraindications āĻāĻŦāĻ‚ Treatment Response-āĻāϰ āĻ“āĻĒāϰ āύāĻŋāĻ°ā§āĻ­āϰ āĻ•āϰ⧇āĨ¤


ā§§ā§Ē. Management / Treatment Review

A. Stroke Secondary Prevention

Non-cardioembolic Ischemic Stroke āĻšāϞ⧇ āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ Single Antiplatelet Therapy āωāĻĒāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Atrial Fibrillation-related Stroke āĻšāϞ⧇ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇ Anticoagulation āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšā§ŸāĨ¤

Aspirin āĻāĻŦāĻ‚ Clopidogrel āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻ⧇ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ…āϧāĻŋāĻ•āĻžāĻ‚āĻļ Stroke āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āύāĻŋ⧟āĻŽāĻŋāϤ āϏ⧁āĻĒāĻžāϰāĻŋāĻļ āĻ•āϰāĻž āĻšā§Ÿ āύāĻžāĨ¤

B. Blood Pressure Control

Neurologically stable Stroke Survivor-āĻāϰ āĻŽāĻ§ā§āϝ⧇ āĻ…āϧāĻŋāĻ•āĻžāĻ‚āĻļ⧇āϰ āϜāĻ¨ā§āϝ Target BP:

<130/80 mmHg

āϤāĻŦ⧇ āϰ⧋āĻ—ā§€āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž, āϏāĻšāύāĻļā§€āϞāϤāĻž āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϰ⧋āĻ— āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤāĻ­āĻžāĻŦ⧇ āϞāĻ•ā§āĻˇā§āϝ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āφāϞāĻžāĻĻāĻž Antihypertensive Drug āĻšā§‹āϖ⧇ āĻĒ⧜āϛ⧇ āύāĻžāĨ¤ āϰ⧋āĻ—ā§€ āφāϗ⧇ āĻĨ⧇āϕ⧇ āϕ⧋āύ⧋ BP Medicine āĻ–āĻžāĻšā§āϛ⧇āύ āĻ•āĻŋ āύāĻž āϤāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

C. Lipid Management

Lipid Profile āĻ“ Stroke Etiology āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āĻŦāĻ°ā§āϤāĻŽāĻžāύ Atorvastatin 10 mg āϝāĻĨ⧇āĻˇā§āϟ āĻ•āĻŋ āύāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

āύāĻŋāĻœā§‡ āĻĨ⧇āϕ⧇ Statin Dose āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤

D. Neuropathic Pain Assessment

Algaba-āĻāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āϰ āϜāĻ¨ā§āϝ Pain Distribution, Character, Severity, Sensory Abnormality āĻ“ Functional Impact āϜāĻžāύāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

E. Spasticity Rehabilitation

Baclofen-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Benefit āĻ“ Risk āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

NICE NG236 āĻ…āύ⧁āϏāĻžāϰ⧇ Generalised Spasticity-āϤ⧇ Oral Baclofen āĻŦāĻŋāĻŦ⧇āĻšā§āϝ; Focal Spasticity-āϤ⧇ āϞāĻ•ā§āĻˇā§āϝāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• Rehabilitation āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻŦ⧇āĻļāĻŋ āĻĒā§āϰāĻžāϏāĻ™ā§āĻ—āĻŋāĻ• āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤


ā§§ā§Ģ. Referral

Primary Referral: Neurology / Neuromedicine

āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• Referral āĻšāϞ⧋ Neurology / NeuromedicineāĨ¤

āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ Physical Medicine & Rehabilitation-āĻāĻ“ Refer āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

Cardiology Referral āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇ āϝāĻĻāĻŋ Atrial Fibrillation, Structural Heart Disease, Heart Failure āĻ…āĻĨāĻŦāĻž Cardioembolic Stroke-āĻāϰ āϏāĻ¨ā§āĻĻ⧇āĻš āĻĨāĻžāϕ⧇āĨ¤

Prescription Referral Note

Referred to Neurology / Neuromedicine Specialist for evaluation of previous ischemic stroke, assessment of possible residual neurological deficits and post-stroke pain/spasticity, medication review, and optimisation of secondary stroke prevention.


ā§§ā§Ŧ. Overview / Summary

✅ Final Working Diagnosis

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āϤāĻĨā§āϝ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āωāĻĒāϝ⧁āĻ•ā§āϤ Diagnosis:

1. H/O Ischemic Stroke
2. H/O Hypertension (HTN)

āĻŦāĻžāĻ‚āϞāĻžā§Ÿ:

āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āχāĻ¸ā§āϕ⧇āĻŽāĻŋāĻ• āĻ¸ā§āĻŸā§āϰ⧋āĻ• āĻ“ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϏāĻšāĻžāĻŦāĻ¸ā§āĻĨāĻžāύāĻ•āĻžāϰ⧀ āϏāĻŽāĻ¸ā§āϝāĻž:

Possible Post-Stroke Neuropathic Pain and/or Spasticity — Clinical Confirmation Required.

Algaba 50 mg āϏāĻ āĻŋāĻ•āĻ­āĻžāĻŦ⧇ āĻļāύāĻžāĻ•ā§āϤ āĻšāĻ“ā§ŸāĻžāϰ āĻĢāϞ⧇ āϰ⧋āĻ—ā§€āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Neuropathic Pain āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻŦā§‡ā§œā§‡āϛ⧇āĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻļ⧁āϧ⧁ Pregabalin āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ Neuropathic Pain āĻŦāĻž Post-Stroke Epilepsy āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Prescription-āĻ Dx āϕ⧀ āϞāĻŋāĻ–āĻŦ⧇āύ?

Dx: H/O Ischemic Stroke with HTN.

āĻŦāĻ°ā§āϤāĻŽāĻžāύ Neurological Examination-āĻ Residual Deficit, Neuropathic Pain āĻ…āĻĨāĻŦāĻž Spasticity āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϞ⧇ āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ Diagnosis āϝ⧁āĻ•ā§āϤ āĻ•āϰāĻŦ⧇āύāĨ¤


ā§§ā§­. Actionable Clinical Plan

Priority 1 — Drug Safety: Reservix 100 mg āϏāĻ¤ā§āϝāĻŋāχ Aceclofenac āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰ⧁āύāĨ¤ Stroke History-āĻāϰ āϏāĻ™ā§āϗ⧇ āĻāϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Safety ConcernāĨ¤

Priority 2 — Neurological Assessment: āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž, Sensory Change, Neuropathic Pain āĻ“ Spasticity āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧁āύāĨ¤

Priority 3 — Stroke Review: āĻĒ⧁āϰ⧋āύ⧋ CT/MRI, Stroke Etiology āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻ•āĻžāĻ—āϜāĻĒāĻ¤ā§āϰ āϏāĻ‚āĻ—ā§āϰāĻš āĻ•āϰ⧁āύāĨ¤

Priority 4 — Risk-factor Assessment: BP, LDL-C, HbA1c, ECG āĻāĻŦāĻ‚ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ Renal Function āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧁āύāĨ¤

Priority 5 — Medication Review: Algaba āĻ“ Beklo-āĻāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž, Response, Renal Dose āĻāĻŦāĻ‚ Sedation/Fall Risk āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰ⧁āύāĨ¤

āύāϤ⧁āύ āĻ•āϰ⧇ āĻāĻ• āĻĒāĻžāĻļ āĻĻ⧁āĻ°ā§āĻŦāϞ āĻšāĻ“ā§ŸāĻž, āĻŽā§āĻ– āĻŦ⧇āρāϕ⧇ āϝāĻžāĻ“ā§ŸāĻž, āĻ•āĻĨāĻž āϜ⧜āĻŋā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž āĻŦāĻž āĻšāĻ āĻžā§Ž āĻĻ⧃āĻˇā§āϟāĻŋāĻļāĻ•ā§āϤāĻŋāϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻšāϞ⧇ āϜāϰ⧁āϰāĻŋ Stroke Service-āĻ āĻĒāĻžāĻ āĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤


ā§§ā§Ž. Reference List

Textbooks

  1. Harrison’s Principles of Internal Medicine. 22nd Edition. McGraw Hill, 2025. Chapter 437: Introduction to Cerebrovascular DiseasesāĨ¤
  2. Katzung’s Basic & Clinical Pharmacology. 16th Edition. McGraw Hill, 2024. Relevant sections on Antiplatelets, Statins, Anticonvulsants and Muscle RelaxantsāĨ¤
  3. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw Hill, 2023. Relevant chapters on Cardiovascular Pharmacology and CNS DrugsāĨ¤

Clinical Guidelines

  1. AHA/ASA (2021). Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021;52:e364–e467. DOI: 10.1161/STR.0000000000000375.
  2. NICE NG236 (2023). Stroke Rehabilitation in Adults.
  3. NICE CG173 (updated 2020). Neuropathic Pain in Adults: Pharmacological Management in Non-specialist Settings.
  4. UK MHRA (2015). Aceclofenac: Updated Cardiovascular Advice.

Drug Reference

  1. MedEx Bangladesh: Ecosprin, ATV, Algaba, Reservix, Losectil āĻāĻŦāĻ‚ Beklo-āĻāϰ Brand-specific Drug MonographsāĨ¤

Final Clinical Conclusion

āφāĻĒāύāĻžāϰ āϏāĻ‚āĻļā§‹āϧāĻŋāϤ Algaba 50 mg = Pregabalin 50 mg MedEx-āĻ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇āĨ¤

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āĻŽā§‚āϞ Diagnosis āĻāĻŦāĻ‚ āφāĻŽāĻžāϰ Working Diagnosis āĻāĻ•āχ: H/O Ischemic Stroke with HTNāĨ¤

āϤāĻŦ⧇ āĻāĻŦāĻžāϰ āĻĻ⧁āϟāĻŋ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦāĻŋāώ⧟ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ:

āĻĒā§āϰāĻĨāĻŽāϤ, Algaba āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ Neuropathic Pain-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§ŸāϤ, Beklo āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ Post-Stroke Spasticity-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

āĻĻ⧁āϟāĻŋāχ Clinical Examination āĻĻāĻŋā§Ÿā§‡ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Medication Safety Finding: Reservix āϝāĻĻāĻŋ Aceclofenac āĻšā§Ÿ, āϤāĻžāĻšāϞ⧇ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Ischemic Stroke-āĻāϰ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻžāχāĻŦāĻŋāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĻā§āϰ⧁āϤ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Md.Rafiqul Islam Lipu.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top